Clinical trial NCT03204227: Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age
Official title: Evaluate the Safety of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by The Company for Vaccine and Biological Production No.1 in Vietnamese Children Aged 9-24 Months
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Japanese Encephalitis
Keywords: Japanese Encephalitis
JECEVAX
Vietnam
Lead sponsor: National Institute of Hygiene and Epidemiology, Vietnam
Sponsor class: OTHER
Collaborators: name: Ministry of Science and Technology, Vietnam
name: Ministry of Health, Vietnam
First posted: 2017-06-29
Enrollment: 220
Sex: ALL
Minimum age (years): 9
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).

Detailed description: Mouse brain-derived Japanese Encephalitis (JE) vaccine was developed in Vietnam since 1989 with the support from WHO and BIKEN institute, Japan. It helped Viet Nam prevents Japanese Encephalitis outbreaks successfully during those years.

However, mouse brain-derived JE vaccine production requires companies to compliance various requirements from WHO. Especially, WHO has a plan to replace the mouse brain-derived JE vaccines with Cell culture-derived JE vaccines.

Vero cell-derived vaccine technology shows many advantages compares to Mouse brain-derived vaccine technology. VABIOTECH has been approved and sponsored by the Ministry of Science and Technology to produce Vero cell - derived JE vaccine. The vaccine demonstrated a good safety and immunogenicity profile in animal models. The vaccine has been proven safety in volunteer adults and in phase 2 which evaluated the safety and immunogenicity of 3 difference antigen concentrations.

In this study, a selected dose of the studied vaccine (JECEVAX) derived from phase 2 will be compared the safety with a licensed vaccine (JEVAX-VABIOTECH Vietnam) in Vietnamese children, aged 9-24 months to assess the safety and immunogenicity. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of investigate vaccines or control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose (up to date of 2nd dose) and from the second dose to 28-34 days after 2nd dose (up to date of 3rd visit). SAE (from start of first dose to 28-34 days after second dose - date of 3rd visit).

Eligibility criteria: Inclusion Criteria:

* Healthy children of both sexes, 9-24 months of age;
* Have not been vaccinated with JE vaccine;
* Parents/legally guardians agree their children to participate in the study and sign the paper informed consent.

Exclusion Criteria:

* Currently has chronic diseases (cardiovascular, liver and spleen related etc);
* Currently has acute diseases;
* Use of immunocompromised treatment within 4 weeks of enrollment;
* Being immunocompromised and autoimmune diseases (HIV, lupus);
* The family history of immunocompromised;
* History of febrile seizure;
* Allergic to any vaccine component;
* Fever (\>38 Celsius degree) within 3 days before vaccination or at enrollment;
* Malnourished (2nd grade or above);
* Blood disorder;
* Use of vaccines which have not been licenced 7 days before enrolment in this study

Primary outcomes:
measure: Percent of participants with treatment-related adverse events during study period.
timeFrame: Up to 28-34 days after 2nd dose
Secondary outcomes:
measure: Frequencies of participants with treatment-related SAE during study period
timeFrame: Up to 28-34 days after the 2nd dose (3rd visit)
Other outcomes:
Locations:
city: Hòa Bình
country: Vietnam
facility: Hoa Binh Provincial Preventive Medicine Center
state: Hoa Binh
city: Hòa Bình
country: Vietnam
facility: Hoa Binh City Health Center
state: Hoa Binh
city: Thanh Son
country: Vietnam
facility: District Health Center
state: Phu Tho
city: Viet tri
country: Vietnam
facility: Phu Tho Preventive Medicine Center
state: Phu Tho
Study officials:
affiliation: National Institute of Hygiene and Epidemiology, Vietnam
name: Thiem D Vu, MD., PhD.
role: PRINCIPAL_INVESTIGATOR
References: